---
title: 'Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab
  after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive
  melanoma: The ImmunoCobiVem phase 2 randomised trial'
date: '2023-07-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37482012/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230724180956&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In patients with BRAF^(V600)-mutated advanced melanoma who
  achieve tumour control with TT, early switch at 3months to atezolizumab led to rapid
  loss of tumour control but provided a numerical OS benefit at 2years compared with
  continued ...'
disable_comments: true
---
CONCLUSION: In patients with BRAF^(V600)-mutated advanced melanoma who achieve tumour control with TT, early switch at 3months to atezolizumab led to rapid loss of tumour control but provided a numerical OS benefit at 2years compared with continued ...